This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Sibylla’s scientific founders come from very different scientific fields that do not usually speak to each other, such as theoretical physics, molecularbiology and pharmaceutical chemistry. And so, I have been the managerial co-founder and CEO of Sibylla since 2017. This multidisciplinary approach is at the heart of Sibylla.
Jasmine has a background in neuroscience and genetic manipulation, with early works focused on using a combined structural and molecularbiology approach to assess disease-associated proteins implicated in Alzheimer’s disease. big pharma or startups/spin off? Where do you enjoy more to work? What pro/cons?
A 2022 survey by McKinsey found that emerging biotech companies are less satisfied with their CROs than large pharmacompanies and reported the feeling of being underserved. Based in Massachusetts, Thermo Fisher Scientific Inc.
” A Global View Even as advances in computing and molecularbiology usher in the era of a new, high-tech “phage therapy 2.0”, ” “Somebody’s just got to break through with good data, even if it’s not us.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
111 
Let's personalize your content